摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(3-Chloro-4-fluorophenyl)methyl](methyl)amine | 381236-43-7

中文名称
——
中文别名
——
英文名称
[(3-Chloro-4-fluorophenyl)methyl](methyl)amine
英文别名
1-(3-chloro-4-fluorophenyl)-N-methylmethanamine
[(3-Chloro-4-fluorophenyl)methyl](methyl)amine化学式
CAS
381236-43-7
化学式
C8H9ClFN
mdl
MFCD16786981
分子量
173.61
InChiKey
NNVXSSJIYYSLSI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    214.5±25.0 °C(Predicted)
  • 密度:
    1.179±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDINE UTILISES EN TANT QU'ANTAGONISTES DE RECEPTEURS D'OREXINE
    申请人:SANOFI AVENTIS
    公开号:WO2005075458A1
    公开(公告)日:2005-08-18
    The present invention relates to the orexin receptor antagonists of the general formula (I), which are selective to orexin I receptors. (I) -wherein Ar stands for phenyl group or a 5- or 6-membered heterocyclic ring containing 1-3 identical or different heteroatoms or methylenedioxyphenyl group -these groups may optionally be substituted with one or more identical or different C1.4 alkyl group, halogen atom, hydroxyl group, C1-4 alkoxy group, trihalogenomethyl group, NHC1.4 alkyl, -N(CI-4 alkyl)2 or -NHC(=0)-C1-4 alkyl group,
    本发明涉及通式(I)的俄利新受体拮抗剂,这些拮抗剂对俄利新I受体具有选择性。其中,Ar代表苯基或含有1-3个相同或不同杂原子或亚甲二氧基苯基的5-或6元杂环的环,这些基团可以选择性地用一个或多个相同或不同的C1.4烷基基团、卤原子、羟基、C1-4烷氧基、三卤甲基基团、NHC1.4烷基、-N(CI-4烷基)2或-NHC(=0)-C1-4烷基基团取代。
  • HIV integrase inhibitors
    申请人:——
    公开号:US20030181490A1
    公开(公告)日:2003-09-25
    The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula 1 wherein R 1 is C 1 -C 4 alkyl, carbocyclic radical, heterocyclic radical, aryl-C 1 -C 2 alkylene, aryloxy-C 1 -C 2 alkylene, alkoxy-CC(O)—, wherein R 1 is optionally substituted from 1-3 times with halo, C 1 -C 2 alkyl or C 1 -C 2 alkoxy, or R 1 is H; R 2 is H or C 1 -C 4 alkyl; R 3 is H, C 1 -C 4 alkyl or phenyl-C 0 -C 2 alkylene which is optionally substituted with 1-3 R 5 ; R 4a is carbocylic radical, heterocyclic radical, aryloxy, aryl-C 1 -C 4 alkylene, aryl-cyclopropylene, aryl-NHC(O)—, wherein R 4a is optionally substituted with 1-3 R 5 ; and wherein each R 5 is independently selected from H, halo, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, R 6 -phenyl, R 6 -phenoxy, R 6 -benzyl, R 6 -benzyloxy, NH 2 C (O)—, alkyl-NHC(O)—, wherein R 6 is H, halo; Z is a bond or a substituted or unsubstituted C 1 -C 4 alkylene group; and B 2 is 2
    本发明涉及抑制HIV整合酶的化合物,并通过给予式1中的化合物治疗艾滋病或ARC,其中R1为C1-C4烷基,碳环基,杂环基,芳基-C1-C2烷基,芳氧基-C1-C2烷基,烷氧基-CC(O)-,其中R1可以用卤素,C1-C2烷基或C1-C2烷氧基从1-3次取代,或R1为H;R2为H或C1-C4烷基;R3为H,C1-C4烷基或苯基-C0-C2烷基,该苯基-C0-C2烷基可以选择性地用1-3个R5取代;R4a为碳环基,杂环基,芳氧基,芳基-C1-C4烷基,芳基环丙基,芳基-NHC(O)-,其中R4a可以选择性地用1-3个R5取代;每个R5都是独立选择的H,卤素,C1-C4烷基,C1-C4烯基,C1-C4卤代烷基,C1-C4烷氧基,R6-苯基,R6-苯氧基,R6-苄基,R6-苄氧基,NH2C(O)-,烷基-NHC(O)-,其中R6为H,卤素;Z为键或取代或未取代的C1-C4烷基;B2为2。
  • 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists
    申请人:——
    公开号:US20040127485A1
    公开(公告)日:2004-07-01
    The present invention relates to diazepine derivatives of formula (I) wherein R represents hydrogen or C 1-4 alkyl; R 1 represents hydrogen or C 1-4 alkyl; R 2 represents trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy or halogen; R 3 represents halogen or C 1-4 alkyl; R 4 represents hydrogen, halogen, C 1-4 alkyl or COR 6 ; R 5 represents hydrogen, C 1-4 alkyl or R 5 together within the R 1 represents C 3-7 cycloalkyl; R 6 represents hydroxy, amino, methylamino, dimethylamino, 5 membered heteroaryl group containing 1 to 3 heteroatoms selected independently from oxygen, sulphur and nitrogen or a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms; m or n are independently zero or an integer from 1 to 3; X and Y are independently NR 7 or methylene; provided that when X is NR 7 , Y is methylene and when X is methylene, Y is NR 7 ; R 7 represents hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; and pharmaceutically acceptable salts and solvates thereof; to process for their preparation and their use in the treatment of condition mediated by tachykinins.
    本发明涉及公式(I)的苯二氮平衍生物,其中R代表氢或C1-4烷基;R1代表氢或C1-4烷基;R2代表三甲基,C1-4烷基,C1-4烷氧基,三甲氧基或卤素;R3代表卤素或C1-4烷基;R4代表氢,卤素,C1-4烷基或COR6;R5代表氢,C1-4烷基或R5与R1一起代表C3-7环烷基;R6代表羟基,基,甲基基,二甲基基,含有1至3个独立选择的氧,和氮杂原子的5元杂环芳基基团或含有1至3个氮原子的6元杂环芳基基团;m或n分别为零或1至3的整数;X和Y分别为NR7或亚甲基;但当X为NR7时,Y为亚甲基,当X为亚甲基时,Y为NR7;R7代表氢,C1-4烷基或C3-7环烷基;以及其药学上可接受的盐和溶剂合物;以及它们在治疗由快速激肽调节的疾病中的应用的制备方法。
  • Piperazine derivatives as tachykinin antagonists
    申请人:——
    公开号:US20040157858A1
    公开(公告)日:2004-08-12
    The present invention relates to piperazine derivatives of formula (I) wherein R and R 1 represent independently halogen or C 1-4 alkyl; R 2 is hydrogen or C 1-4 alkyl; n and m are independently 1 or 2 and pharmaceutically acceptable salts and solvates thereof, to process for their preparation, to pharmaceutical compositions containing them and to their medical use. 1
    本发明涉及式(I)的哌嗪生物,其中R和R1分别代表卤素或C1-4烷基;R2为氢或C1-4烷基;n和m分别独立为1或2,并且其药学上可接受的盐和溶剂化合物,以及制备它们的过程,包含它们的制药组合物和它们的医药用途。
  • Tachykinin Antagonists
    申请人:Alvaro Guiseppe
    公开号:US20070135414A1
    公开(公告)日:2007-06-14
    The present invention relates to diazepine derivatives of formula (I) wherein R represents hydrogen or C 1-4 alkyl; R 1 represents hydrogen or C 1-4 alkyl; R 2 represents trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy or halogen; R 3 represents halogen or C 1-4 alkyl; R 4 represents hydrogen, halogen, C 1-4 alkyl or COR 6 ; R 5 represents hydrogen, C 1-4 alkyl or R 5 together within the R 1 represents C 3-7 cycloalkyl; R 6 represents hydroxy, amino, methylamino, dimethylamino, 5 membered heteroaryl group containing 1 to 3 heteroatoms selected independently from oxygen, sulphur and nitrogen or a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms; m or n are independently zero or an integer from 1 to 3; X and Y are independently NR 7 or methylene; provided that when X is NR 7 , Y is methylene and when X is methylene, Y is NR 7 ; R 7 represents hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; and pharmaceutically acceptable salts and solvates thereof; to process for their preparation and their use in the treatment of condition mediated by tachykinins
    本发明涉及式(I)的苯二氮平衍生物,其中:R表示氢或C1-4烷基;R1表示氢或C1-4烷基;R2表示三甲基、C1-4烷基、C1-4烷氧基、三甲氧基或卤素;R3表示卤素或C1-4烷基;R4表示氢、卤素、C1-4烷基或COR6;R5表示氢、C1-4烷基或R5与R1一起表示C3-7环烷基;R6表示羟基、基、甲基基、二甲基基、含有1-3个杂原子(独立选择自氧、和氮)的5元杂环芳基基团或含有1-3个氮原子的6元杂环芳基基团;m或n独立地为零或1-3的整数;X和Y独立地为NR7或亚甲基;但当X为NR7时,Y为亚甲基,当X为亚甲基时,Y为NR7;R7表示氢、C1-4烷基或C3-7环烷基;以及其药学上可接受的盐和溶剂合物;以及制备它们的方法和它们在治疗由速激肽介导的疾病中的应用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫